Use of GnRH Agonists in Men Without Prostate Cancer Diagnosis
Author Information
Author(s): Kuo Yong-fang, Goodwin James S, Shahinian Vahakn B
Primary Institution: University of Texas Medical Branch
Hypothesis
Some men receive GnRH agonists after only a limited work-up for their cancer.
Conclusion
Reliance solely on tumor registry data may underestimate the rate of GnRH agonist use in men with prostate cancer.
Supporting Evidence
- 8.9% of incident GnRH agonist users had no diagnosis of prostate cancer registered in SEER.
- Men with higher comorbidity were more likely to lack a SEER diagnosis.
- Procedures like radical prostatectomy were associated with a lower likelihood of not having a SEER diagnosis.
Takeaway
Some men are getting treated for prostate cancer without being officially diagnosed, which means we might not know how many are actually using certain treatments.
Methodology
Linked SEER-Medicare data was used to identify GnRH agonist use in men with or without a registered prostate cancer diagnosis.
Potential Biases
Potential bias due to reliance on Medicare claims data, which may not capture all relevant patient characteristics.
Limitations
The study may overestimate the proportion of GnRH agonist users not captured by SEER registries due to methodological issues.
Participant Demographics
Men aged 67 years and older, with a focus on those receiving GnRH agonists for prostate cancer.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 7.8%–10.1%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website